Gossamer Bio is planning to soon launch a Phase 3 clinical trial to test its experimental inhaled therapy seralutinib…
Articles by Marisa Wexler, MS
Many people with pulmonary arterial hypertension (PAH) report better mental and physical health following the start of the COVID-19…
Balloon pulmonary angioplasty, or BPA, can be an effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), a new study…
Statistical models using U.S. insurance data can help to predict the risk of hospitalization within one year of starting on…
Measuring blood levels of three molecules — SAM, guanine, and NT-proBNP — could help identify pulmonary arterial hypertension (PAH)…
A noninvasive measure of heart and blood vessel function called the TAPSE/PASP ratio could help prioritize people with pulmonary…
Treatment with Pulnovo Medical’s pulmonary artery denervation (PADN) device significantly reduced the risk of clinical worsening among people with…
The experimental therapy levosimendan has been awarded a U.S. patent covering its use for pulmonary hypertension and heart failure…
Treatment with phosphodiesterase-5 (PDE5) inhibitors can improve blood flow parameters and exercise capacity in people with pulmonary hypertension (PH),…
The U.S. Food and Drug Administration (FDA) has approved the third generation of Genosyl, Vero Biotech‘s tankless system for…
Over the past year, the team here at Pulmonary Hypertension News has brought you up-to-date coverage of the latest developments…
Merck’s investigational inhaled treatment MK-5475 was well-tolerated and showed promise among adults with pulmonary arterial hypertension (PAH) in a…